Artelo Biosciences, Inc. ARTL
Set alert
As of Nov 3, 11:14 AM ET
- YTD
- -93.44%
- 1 year
- -97.33%
- Open
- 2.14
- Prev close
- 2.17
- Mkt cap
- 1.18M
- Vol
- 8.53K
- Avg vol
- 484.73K
- EPS
- -136.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.12
- High
- 2.20
- Forward P/E
- -1.10
- Beta
- 1.35
- Short ratio
- 1.65
- Inst. own
- 0.72%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.13
- 200-d avg
- 1.28
- 1y target
- 5.00
Key statistics
- Market cap
- 3.13M
- Enterprise value
- -1.71M
- Trailing P/E
- 0.00
- Forward P/E
- -1.10
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.26
- EPS (TTM)
- -2.87
- Beta
- 1.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.61M
- Total cash
- 5.60M
- Total debt
- 120.00K
- Return on equity
- -88.58%
- Shares outstanding
- 3.23M
- Short % of float
- 0.62%
- 50-day average
- 1.13
- 200-day average
- 1.28
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 5.00
- Target (high)
- 6.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.38.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.41 | -0.35 | +0.06 | +14.63% |
| Aug 13, 2024 | Jun 1, 2024 | -0.83 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.83 | -0.75 | +0.08 | +9.64% |
| May 13, 2024 | Mar 1, 2024 | -1.05 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -1.05 | -0.78 | +0.27 | +25.71% |
| Mar 25, 2024 | Dec 1, 2023 | -0.29 | -0.99 | -0.70 | -241.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Artelo Biosciences, Inc.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- artelobio.com
News
- Artelo Biosciences To Present Data For Its ART27.13 To Treat Chemotherapy-Induced Neuropathic Pain At IASP 2026 World Congress On Pain
- Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
- Artelo Bioscience To Present Data On ART26.12 Program At IASP 2026 World Congress On Pain, October 26–30; Growing Body Of Data Supports ART26.12’s Potential As A Novel, Non-Opioid Treatment For Pain Ahead Of Planned Multiple Ascending Dose Study
- Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
- Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Rises 104.7%
- Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
- Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in September
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
Your note
Sign in to keep a note on ARTL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.54% | 17,350 | 16.83K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.16% | 5,183 | 5.03K | Sep 29, 2024 |
| Rothschild Investment LLC | 0.00% | 8 | 7 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 26 | 25 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 20 | 19 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.32% | 10,443 | 10.13K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 3,253 | 3.15K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 3,048 | 2.96K | Oct 30, 2024 |